These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 20302552

  • 1. Evidence for the efficacy of ARBs across the cardiovascular continuum.
    Gupta M, Honos GN, Velazquez EJ, Chung N, Oigman W, Maggioni AP.
    Curr Med Res Opin; 2010 May; 26(5):1203-18. PubMed ID: 20302552
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 4. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT.
    J Am Board Fam Med; 2009 Mar; 22(6):686-97. PubMed ID: 19897698
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 7. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 8. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 9. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 10. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M.
    QJM; 2012 Jan 21; 105(1):11-27. PubMed ID: 22011630
    [Abstract] [Full Text] [Related]

  • 11. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 21; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 12. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov 21; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M.
    Am J Cardiol; 2007 Aug 06; 100(3A):38J-44J. PubMed ID: 17666197
    [Abstract] [Full Text] [Related]

  • 14. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
    McFarlane SI.
    Expert Rev Cardiovasc Ther; 2009 Nov 06; 7(11):1363-71. PubMed ID: 19900019
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Weber MA.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun 06; 4(2):62-73. PubMed ID: 12806587
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.
    Chrysant SG.
    Clin Ther; 2008 Jun 06; 30 Pt 2():2181-90. PubMed ID: 19281913
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future.
    Weber M.
    J Renin Angiotensin Aldosterone Syst; 2001 Sep 06; 2 Suppl 2():S12-6. PubMed ID: 11881103
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 06; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 19. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V.
    J Hypertens Suppl; 2005 Apr 06; 23(1):S9-17. PubMed ID: 15821452
    [Abstract] [Full Text] [Related]

  • 20. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, Haffner SM, Bethel MA, Holman RR, Califf RM.
    Cardiovasc Ther; 2010 Apr 06; 28(2):124-32. PubMed ID: 20184589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.